TMDX - NASDAQ
TransMedics Group, Inc.
$69.69
+3.2%TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
At a Glance
Live SnapshotTransMedics Group, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.
TransMedics Group, Inc. Income Statement
TMDX • NASDAQ
| TransMedics Group, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
605.5M | 441.5M | 241.6M | 93.5M | 30.3M | 25.6M | 23.6M | 13M | 7.7M | 6.2M | |
GROSS PROFIT | ||||||||||
(242.7M) | (179.5M) | (87.5M) | (28.2M) | (9.1M) | (9M) | (9.7M) | (7.3M) | (5.5M) | (5.4M) | |
362.8M | 262.1M | 154.1M | 65.3M | 21.2M | 16.6M | 13.9M | 5.7M | 2.1M | 766K | |
OPERATING INCOME | ||||||||||
(254.2M) | (224.6M) | (182.8M) | (96.7M) | (60.6M) | (43M) | (43.5M) | (26M) | (22.6M) | (23.8M) | |
(185.2M) | (168.6M) | (119.6M) | (69.9M) | (38.3M) | (24.2M) | (23.6M) | (12.3M) | (7.6M) | (8.1M) | |
(69.1M) | (56M) | (63.3M) | (26.8M) | (22.3M) | (18.8M) | (19.9M) | (13.7M) | (15M) | (15.6M) | |
108.6M | 37.5M | -28.7M | -31.4M | -39.4M | -26.4M | -29.6M | -20.2M | -20.4M | -23M | |
PRE-TAX INCOME | ||||||||||
(13.8M) | (14.4M) | (10.8M) | (3.7M) | (3.9M) | (4M) | (4.4M) | (2.4M) | (1.1M) | (979K) | |
-13.8M | -14.4M | 1.7M | -2.8M | -3.9M | -2.3M | -3.6M | -2.4M | -524K | -974K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -213K | (0.0) | (5K) | |
-1.1M | -1.7M | 2.1M | -4.7M | -4.8M | -2.3M | -3.9M | -3.5M | -365K | -1.1M | |
107.5M | 35.8M | -26.7M | -36.2M | -44.2M | -28.7M | -33.5M | -23.7M | -20.8M | -24.1M | |
NET INCOME | ||||||||||
-82.8M | (316K) | -1.6M | (66K) | (36K) | (32K) | (40K) | (41K) | (32K) | (0.0) | |
190.3M | 35.5M | -25M | -36.2M | -44.2M | -28.7M | -33.5M | -23.8M | -20.8M | -24.1M |
SEC Filings
TMDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | October 29, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TMDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.